Elsevier

Regulatory Peptides

Volume 20, Issue 1, January 1988, Pages 33-44
Regulatory Peptides

Unidirectional uptake of enkephalins at the blood-tissue interface of the blood-cerebrospinal fluid barrier: a saturable mechanism

https://doi.org/10.1016/0167-0115(88)90055-9Get rights and content

Abstract

The cellular uptake at the blood-tissue interface of the blood-cerebrospinal fluid (CSF) barrier to tyrosyl-3,5-[3H]enkephalin-[5-l-leucine] (abbreviated to Leu-enkephalin) and of its synthetic analogue d-alanine2-tyrosyl-3,5-[3H]enkephalin-[5-d-leucine] (abbreviated to d-Ala2-d-Leu5-enkephalin) was studied in the isolated perfused choroid plexuses from the lateral ventricles of the sheep, using the rapid (<30 s), single circulation, paired-tracer dilution technique, in which d-[14C]-mannitol serves as an extracellular marker. Cellular uptake of peptides was estimated by directly comparing venous dilution profiles of [3H] and [14C] radioactivities in the absence and presence of unlabelled peptide, the N-terminal amino acid (l-tyrosine), the typical l-transport system substrate, 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid (BCH) and the inhibitor of aminopeptidase activity, bacitracin. The cellular uptake of both enkephalins was strongly (65–76%) but not completely inhibited by the addition of 5 mM unlabelled peptide to the bolus; the self-inhibition was significantly higher for d-Ala2-d-Leu5-enkephalin than for Leu-enkephalin. The addition to the bolus of l-tyrosine (5 mM), BCH (10 mM) or bacitracin (2 mM) reduced the 3H-radioactivity uptake by the choroid plexus of both enkephalins by 20–40%, the degree of inhibition being greater for [3H]-Leu-enkephalin than for its analogue.

It is concluded that during single passage of enkephalins through the choroid plexus circulation, unidirectional uptake at the blood-tissue interface of the blood-CSF barrier consists of two components; a saturable component, which represents uptake of the intact peptide by the choroid epithelium, and a non-saturable component, which reflects enzymatic degradation of peptide in the blood and/or at the barrier, with a liberation of the N-terminal tyrosyl residue. Higher penetration of the blood-CSF barrier by d-Ala2-d-Leu5-enkephalin can be attributed to its greater resistance to hydrolysis.

References (41)

  • W.M. Pardridge et al.

    Enkephalins and the blood-brain barrier; studies of binding and degradation in isolated brain microvessels

    Endocrinology

    (1981)
  • B.V. Zlokovic et al.

    Measurement of solute transport across the blood-brain barrier in the perfused guinea-pig brain: method and application to N-methyl-alpha-aminoisobutyric acid

    J. Neurochem.

    (1986)
  • B.V. Zlokovic et al.

    Transport of leucine-enkephalin across the blood-brain barrier in the perfused guinea-pig brain

    J. Neurochem.

    (1987)
  • W.M. Pardridge

    Neuropeptides and the blood-brain barrier

    Annu. Rev. Physiol.

    (1983)
  • W.M. Pardridge

    Receptor-mediated peptide transport through the blood-brain barrier

    Endocr. Rev.

    (1986)
  • H. Davson

    The blood-brain barrier

    J. Physiol. (Lond.)

    (1976)
  • H. Davson et al.

    Physiology and pathophysiology of the cerebrospinal fluid

  • M. Bradbury

    The concept of a blood-brain barrier

  • M.B. Segal et al.

    The secretion of cerebrospinal fluid

  • R. Deane et al.

    The transport of sugars across the perfused choroid plexus of the sheep

    J. Physiol. (Lond.)

    (1985)
  • Cited by (22)

    View all citing articles on Scopus
    View full text